TransCode Therapeutics: Targeting Multiple Metastatic Cancers Using RNA
Mar. 18, 2022
TransCode Therapeutics (Nasdaq: RNAZ) is developing therapeutic and diagnostic candidates designed to deliver on the promise of RNA in oncology. The Company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas and others. The Company intends to file an exploratory investigational new drug (IND) application for its first in human clinical trial and in parallel complete IND-enabling studies for TTX-MC138 to file an IND for a Phase I/II clinical trial. A second RNAi based program is TTX-siPDL1, a small interfering RNA (siRNA)–based modulator of programmed death-ligand 1 (PD-L1). TransCode also has three cancer agnostic programs—TTX-RIGA, an RNA–based agonist programmed to elicit an immune response against cancer cells; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or deletion of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. Visit RNAZinfo.com to learn more.
